original article Wien Klin Wochenschr (2017) 129:545–551 DOI 10.1007/s00508-017-1205-z Filgrastim-alone versus pegylated ﬁlgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients Barbara Skopec · Matevz Skerget · Darja Zontar · Vesna Zadnik · Samo Zver Received: 17 August 2016 / Accepted: 31 March 2017 / Published online: 24 April 2017 © Springer-Verlag Wien 2017 Summary median time to neutrophil and platelet engraftment Background Autologous hematopoietic stem cell was 13 days and 16.5 days for ﬁlgrastim and 13 days transplantation (aHSCT) is the recommended stan- and 16 days for pegﬁlgrastim group. dard upfront treatment for transplant eligible myeloma Conclusions We can conclude that pegﬁlgrastim alone patients. Considering possible complications related is at least equally successful as ﬁlgrastim alone for to chemotherapy–cytokine mobilization, cytokine- the PBSC mobilization in newly diagnosed myeloma alone mobilization is often used. We compared mo- patients. bilization with ﬁlgrastim alone to pegﬁlgrastim alone in newly diagnosed myeloma patients after induction Keywords Multiple myeloma · Autologous stem cell treatment with bortezomib and dexamethasone. The transplantation · Mobilization · Pegﬁlgrastim · Filgras- comparison was made between peripheral blood stem tim cell (PBSC) yields, number of apheresis, hematopoi- etic stem cell subsets, and time to
Wiener klinische Wochenschrift – Springer Journals
Published: Apr 24, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera